verapamil has been researched along with Myocardial Ischemia in 115 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "CLINICAL TRIALS WITH VERAPAMIL AND TRANDOLAPRIL: In the Danish Verapamil Infarction Trial II, verapamil improved survival in patients without heart failure but had no effect in patients with heart failure who were receiving diuretic treatment." | 10.18 | Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial. ( Hansen, JF, 1998) |
| "The antianginal efficacy of 240 mg sustained release verapamil once daily doses and 300 mg diltiazem was studied in 20 normotensive patients with chronic stable angina pectoris, using a randomized, double-blind crossover design." | 9.08 | Antianginal efficacy over 24 hours and exercise hemodynamic effects of once daily sustained-release 300 mg diltiazem and 240 mg verapamil in stable angina pectoris. ( Ciaburri, F; De Rosa, ML; Della Guardia, D; Giordano, A; Melfi, M; Rengo, F, 1998) |
| "The present review discusses the prognostic significance of post-infarction angina pectoris, and the significance of post-infarction intervention with verapamil on the prevalence of post-infarction ischaemia and prognosis." | 8.79 | Anti-ischaemic intervention with verapamil in patients recovering from acute myocardial infarction. ( Jespersen, CM, 1995) |
| "Hesperetin (HSP) is a natural flavonoid that offers useful curative effects for cardiovascular diseases, but its effect on myocardial ischemia and its precise mechanism remains unclear." | 8.02 | Hesperetin modulates the Sirt1/Nrf2 signaling pathway in counteracting myocardial ischemia through suppression of oxidative stress, inflammation, and apoptosis. ( Chu, L; Han, X; Jing, X; Li, J; Liu, M; Liu, P; Xue, Y; Zhang, M; Zhang, Y, 2021) |
| "To assess effect of calcium antagonists amlodipine and verapamil on the risk of development of atrial fibrillation after coronary artery bypass surgery." | 7.72 | [Effect of calcium antagonists verapamil and amlodipine on the risk of development of atrial fibrillation after coronary artery bypass grafting]. ( Afanas'ev, SA; Akhmedov, ShD; Antonchenko, IV; Dzhavadova, GK; Evtushenko, AV; Kandinskiĭ, ML; Kozlov, BN; Popov, SV; Shipulin, VM; Vecherskiĭ, IuIu, 2003) |
| "This study was designed to investigate whether two L-type calcium antagonists, verapamil and nicardipine reduce the myocardial necrosis (infarct size) following ischemia and reperfusion." | 7.70 | [Comparison of effects of verapamil and those of nicardipine on myocardial ischemia and reperfusion injury: a study in an in situ rabbit model]. ( Furuya, M; Yoshida, K, 1999) |
| "During the ischemic period, the low (clinically relevant) dose of mibefradil prevented the fall of the ventricular fibrillation threshold, without depressing the maximal rate of pressure development of the left ventricle (LVmax dP/dt)." | 7.70 | Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise. ( Hofmann, D; McCarthy, J; Muller, CA; Opie, LH; Peisach, M; Pineda, CA, 1998) |
| ") administration of (+/-) propranolol (100-200-300 microg/animal/day, during 7 days) or (+/-) verapamil (40-80-160 microg/animal/day, during 7 days) afforded a significant protection (with the exception of the lowest dose) on the investigated parameters: arrhythmias, ischemic zone (in coronary ligated rats), lactate dehydrogenase and aspartate aminotransferase activity of the serum, focal necrosis (in isoproterenol treated rats)." | 7.70 | The influence of intracerebroventricular administration of (+/-) propranolol and (+/-) verapamil on experimental myocardial ischemia and necrosis in rats. ( Blidaru, M; Cuparencu, B; Pleşca-Manea, L, 2000) |
| " The effects of the calcium channel blockers, verapamil and nifedipine on myocardial ischaemia and oedema evoked by endothelin-1 (ET-1) or IRL 1620, an ETB receptor-selective agonist were studied in anaesthetized and conscious rats." | 7.69 | Effects of calcium antagonists on endothelin-1-induced myocardial ischaemia and oedema in the rat. ( Filep, JG; Földes-Filep, E; Fournier, A; Skrobik, Y, 1996) |
| "The authors evaluated the effects of verapamil (Ve) and magnesium sulfate (Mg) on the electrophysiologic changes induced in dogs during acute myocardial ischemia and following reperfusion." | 7.69 | Effects of verapamil and magnesium sulfate on electrophysiologic changes during acute myocardial ischemia and following reperfusion in dogs: comparative effects of administration by intravenous and coronary sinus retroperfusion routes. ( Bando, S; Yamamoto, K, 1996) |
| "The effects of the specific bradycardic agent, zatebradine (UL-FS 49), on ventricular arrhythmias occurring during an acute ischemia were compared to those of verapamil." | 7.69 | Effect of zatebradine, a specific bradycardic agent, on ischemia-induced arrhythmias in anesthetized rabbits. ( Bril, A; Cheval, B; Forest, MC; Gout, B; Landais, L, 1994) |
| "Effect of verapamil on myocardial ischemia in patients with hypertrophic cardiomyopathy (HCM) was evaluated by exercise stress myocardial 201Tl SPECT (EX-Tl)." | 7.68 | [Effect of verapamil on myocardial ischemia in patients with hypertrophic cardiomyopathy: evaluation by exercise 201Tl SPECT]. ( Azuma, A; Kohno, Y; Nakagawa, M; Nakagawa, T; Nakamura, T; Ootsuki, K; Shiga, K; Sugihara, H; Taniguchi, Y; Umamoto, I, 1993) |
| "In the verapamil group ventricular arrhythmias increased from 25 to 33% (NS)." | 6.67 | Ventricular arrhythmias in patients recovering from myocardial infarction: do residual myocardial ischemia and anti-ischemic medical intervention influence the one-month prevalence? The Danish Study Group on Verapamil in Myocardial Infarction. ( Jespersen, CM; Vaage-Nilsen, M, 1993) |
| "CLINICAL TRIALS WITH VERAPAMIL AND TRANDOLAPRIL: In the Danish Verapamil Infarction Trial II, verapamil improved survival in patients without heart failure but had no effect in patients with heart failure who were receiving diuretic treatment." | 6.18 | Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial. ( Hansen, JF, 1998) |
| "Mibefradil is a new calcium antagonist that can inhibit cardiac calcium current without reducing myocardial force development." | 5.29 | The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. ( Billman, GE; Hamlin, RL, 1996) |
| " Initial dose-response studies for anipamil (0." | 5.29 | Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia. ( Guppy, LJ; Harvie, CJ; Pugsley, MK; Ries, CR; Walker, MJ, 1995) |
| "The hypotensive and antiischemic activity of combined therapy with dihydropyridine group (amlodipine) and non-dihydropyridine group (verapamil retard) calcium antagonists (CA) as well as tolerance to this therapy were studied in 43 patients suffering from coronary heart disease (CAD) with II-III functional class exertional angina and II degree essential hypertension during 24 weeks." | 5.12 | [Evaluation of hypotensive and antiischemic effects of a combination of dihydropyridine and non-dihydropyridine calcium antagonists in patients suffering from coronary artery disease with arterial hypertension]. ( Abramova, GN; Berenshteĭn, NV; Burmistrova, LF; Iskendeerov, BG; Lokhina, TV; Shibaeva, TM, 2006) |
| "The prognostic significance of ambulatory ischemia, alone and in relation to ischemia during exercise was assessed in 686 patients (475 men) with chronic stable angina pectoris taking part in the Angina Prognosis Study In Stockholm (APSIS), who had 24-hour ambulatory electrocardiographic registrations and exercise tests at baseline (n = 678) and after 1 month (n = 607) of double-blind treatment with metoprolol or verapamil." | 5.09 | Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]). ( Björkander, I; Eriksson, SV; Forslund, L; Held, C; Hjemdahl, P; Rehnqvist, N, 1999) |
| " To evaluate the effect of antihypertensive treatment on cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), we studied 46 hypertensive patients with LVH, divided into four groups randomly treated with enalapril, hydrochlorothiazide (HCTZ), atenolol, or verapamil (SR-V) for 6 months." | 5.09 | Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. ( Abrignani, MG; Barbagallo, M; Dominguez, LJ; Nardi, E; Novo, G; Novo, S; Strano, A, 2001) |
| "The antianginal efficacy of 240 mg sustained release verapamil once daily doses and 300 mg diltiazem was studied in 20 normotensive patients with chronic stable angina pectoris, using a randomized, double-blind crossover design." | 5.08 | Antianginal efficacy over 24 hours and exercise hemodynamic effects of once daily sustained-release 300 mg diltiazem and 240 mg verapamil in stable angina pectoris. ( Ciaburri, F; De Rosa, ML; Della Guardia, D; Giordano, A; Melfi, M; Rengo, F, 1998) |
| "The effects of verapamil, nifedipine, propranolol, and combinations of nifedipine+propranolol and nifedipine+verapamil were studied in 60 patients with stable angina pectoris." | 5.07 | [Effect of various antianginal agents on the frequency and duration of myocardial ischemic episodes in patients with stable angina pectoris]. ( Lysenko, AF; Voronkov, LG, 1992) |
| "The present review discusses the prognostic significance of post-infarction angina pectoris, and the significance of post-infarction intervention with verapamil on the prevalence of post-infarction ischaemia and prognosis." | 4.79 | Anti-ischaemic intervention with verapamil in patients recovering from acute myocardial infarction. ( Jespersen, CM, 1995) |
| "Hesperetin (HSP) is a natural flavonoid that offers useful curative effects for cardiovascular diseases, but its effect on myocardial ischemia and its precise mechanism remains unclear." | 4.02 | Hesperetin modulates the Sirt1/Nrf2 signaling pathway in counteracting myocardial ischemia through suppression of oxidative stress, inflammation, and apoptosis. ( Chu, L; Han, X; Jing, X; Li, J; Liu, M; Liu, P; Xue, Y; Zhang, M; Zhang, Y, 2021) |
| " James Women Take Heart (WTH; women without coronary disease at baseline), Women's Ischemia Syndrome Evaluation (women with signs/symptoms of ischemia at baseline), and the INternational VErapamil-Trandolapril STudy (INVEST; women with coronary artery disease and hypertension at baseline), totaling 15,108 adult women with no hypertension, non-RH (blood pressure [BP] ≥140/90 mmHg on ≤2 drugs or BP <140/90 mmHg on 1-3 drugs), or aRH (BP ≥140/90 mmHg on ≥3 drugs or anyone on ≥4 drugs) at baseline." | 3.83 | Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. ( Cooper-DeHoff, RM; Gong, Y; Gulati, M; Handberg, E; Huo, T; Merz, CN; Pepine, CJ; Smith, SM, 2016) |
| "To assess effect of calcium antagonists amlodipine and verapamil on the risk of development of atrial fibrillation after coronary artery bypass surgery." | 3.72 | [Effect of calcium antagonists verapamil and amlodipine on the risk of development of atrial fibrillation after coronary artery bypass grafting]. ( Afanas'ev, SA; Akhmedov, ShD; Antonchenko, IV; Dzhavadova, GK; Evtushenko, AV; Kandinskiĭ, ML; Kozlov, BN; Popov, SV; Shipulin, VM; Vecherskiĭ, IuIu, 2003) |
| "Verapamil and amlodipine produced a potent antiischemic effect and reduced the area of myocardial infarction in rats." | 3.72 | Oxygen-dependent mechanisms underlying the antiischemic effect of verapamil and amlodipine. ( Gatsura, SV, 2004) |
| "This study was designed to investigate whether two L-type calcium antagonists, verapamil and nicardipine reduce the myocardial necrosis (infarct size) following ischemia and reperfusion." | 3.70 | [Comparison of effects of verapamil and those of nicardipine on myocardial ischemia and reperfusion injury: a study in an in situ rabbit model]. ( Furuya, M; Yoshida, K, 1999) |
| ") administration of (+/-) propranolol (100-200-300 microg/animal/day, during 7 days) or (+/-) verapamil (40-80-160 microg/animal/day, during 7 days) afforded a significant protection (with the exception of the lowest dose) on the investigated parameters: arrhythmias, ischemic zone (in coronary ligated rats), lactate dehydrogenase and aspartate aminotransferase activity of the serum, focal necrosis (in isoproterenol treated rats)." | 3.70 | The influence of intracerebroventricular administration of (+/-) propranolol and (+/-) verapamil on experimental myocardial ischemia and necrosis in rats. ( Blidaru, M; Cuparencu, B; Pleşca-Manea, L, 2000) |
| "During the ischemic period, the low (clinically relevant) dose of mibefradil prevented the fall of the ventricular fibrillation threshold, without depressing the maximal rate of pressure development of the left ventricle (LVmax dP/dt)." | 3.70 | Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise. ( Hofmann, D; McCarthy, J; Muller, CA; Opie, LH; Peisach, M; Pineda, CA, 1998) |
| " The effects of diltiazem, verapamil, and nifedipine on extracellular potassium concentration ([K+]e), acidosis, and level of metabolic markers were examined during 30-min global ischemia and postischemic left ventricular (LV) function in isolated guinea pig hearts." | 3.70 | Temporal differences in actions of calcium channel blockers on K+ accumulation, cardiac function, and high-energy phosphate levels in ischemic guinea pig hearts. ( Nagao, T; Sato, R; Yamazaki, J, 1999) |
| " Mibefradil was compared with (+/-)-verapamil for effects on ischaemia- and reperfusion-induced ventricular fibrillation (VF), and the role of ischaemia-selective L-channel block was examined." | 3.70 | Inadequate ischaemia-selectivity limits the antiarrhythmic efficacy of mibefradil during regional ischaemia and reperfusion in the rat isolated perfused heart. ( Curtis, MJ; Farkas, A; Qureshi, A, 1999) |
| "The effects of the specific bradycardic agent, zatebradine (UL-FS 49), on ventricular arrhythmias occurring during an acute ischemia were compared to those of verapamil." | 3.69 | Effect of zatebradine, a specific bradycardic agent, on ischemia-induced arrhythmias in anesthetized rabbits. ( Bril, A; Cheval, B; Forest, MC; Gout, B; Landais, L, 1994) |
| "The authors evaluated the effects of verapamil (Ve) and magnesium sulfate (Mg) on the electrophysiologic changes induced in dogs during acute myocardial ischemia and following reperfusion." | 3.69 | Effects of verapamil and magnesium sulfate on electrophysiologic changes during acute myocardial ischemia and following reperfusion in dogs: comparative effects of administration by intravenous and coronary sinus retroperfusion routes. ( Bando, S; Yamamoto, K, 1996) |
| "Contrast-enhanced magnetic resonance (MR) imaging was used to detect and quantify the extent of myocardial injury after a brief coronary occlusion and reperfusion in response to verapamil treatment in a rat model of left ventricular hypertrophy (LVH)." | 3.69 | Verapamil reduces the size of reperfused ischemically injured myocardium in hypertrophied rat hearts as assessed by magnetic resonance imaging. ( Derugin, N; Higgins, CB; Lauerma, K; Saeed, M; Wendland, MF; Yu, KK, 1996) |
| " The effects of the calcium channel blockers, verapamil and nifedipine on myocardial ischaemia and oedema evoked by endothelin-1 (ET-1) or IRL 1620, an ETB receptor-selective agonist were studied in anaesthetized and conscious rats." | 3.69 | Effects of calcium antagonists on endothelin-1-induced myocardial ischaemia and oedema in the rat. ( Filep, JG; Földes-Filep, E; Fournier, A; Skrobik, Y, 1996) |
| "Effect of verapamil on myocardial ischemia in patients with hypertrophic cardiomyopathy (HCM) was evaluated by exercise stress myocardial 201Tl SPECT (EX-Tl)." | 3.68 | [Effect of verapamil on myocardial ischemia in patients with hypertrophic cardiomyopathy: evaluation by exercise 201Tl SPECT]. ( Azuma, A; Kohno, Y; Nakagawa, M; Nakagawa, T; Nakamura, T; Ootsuki, K; Shiga, K; Sugihara, H; Taniguchi, Y; Umamoto, I, 1993) |
| " The effects of Ro 40-5967 on the susceptibility to ventricular fibrillation were investigated and compared to diltiazem." | 3.68 | Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation. ( Billman, GE, 1992) |
| "In the verapamil group ventricular arrhythmias increased from 25 to 33% (NS)." | 2.67 | Ventricular arrhythmias in patients recovering from myocardial infarction: do residual myocardial ischemia and anti-ischemic medical intervention influence the one-month prevalence? The Danish Study Group on Verapamil in Myocardial Infarction. ( Jespersen, CM; Vaage-Nilsen, M, 1993) |
| "Safety in the drug treatment of hypertension can only be seen in relation to efficacy, which has now come to mean not just blood pressure (BP) reduction but improvements in hard end points including mortality." | 2.40 | Calcium channel blockers for hypertension: dissecting the evidence for adverse effects. ( Opie, LH, 1997) |
| "Ventricular arrhythmias are significantly associated with arrhythmic as well as non-arrhythmic death." | 2.39 | Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil. ( Jespersen, CM, 1996) |
| "Cardiac arrhythmia was measured by electrocardiogram (ECG) and Cx43 protein was determined by immunohistochemistry and western blotting." | 1.39 | Anti-arrhythmic effect of verapamil is accompanied by preservation of cx43 protein in rat heart. ( Chen, M; Pei, JM; Wang, QL; Wu, Q; Zhang, SM; Zhou, P, 2013) |
| " However, the direct cardiotoxicity in vitro and its mechanisms of toxic action remain unclear." | 1.38 | Direct cardiac toxicity of the tentacle-only extract from the jellyfish Cyanea capillata demonstrated in isolated rat heart. ( Beilei, W; Jia, L; Liang, X; Liming, Z; Lin, Z; Qian, H; Qianqian, W; Tao, W; Xiaojuan, W; Xuting, Y, 2012) |
| " Chronic administration (45 days) produced no toxic effects in vital organs and systems of Wistar rats and ISIAH rats." | 1.37 | Glycidipine, a promising hypotensive and cardioprotective agent. ( Belenichev, IF; Bryzgalov, AO; Khvostov, MV; Pavlov, SV; Tolstikova, TG, 2011) |
| "Drug treatment of hypertrophic cardiomyopathy is the first-line treatment, at the onset of clinical signs and symptoms." | 1.35 | [Drug treatment for hypertrophic cardiomyopathy]. ( Gibelin, P, 2009) |
| "Verapamil or saline was given into the LAD artery either at the time the coronary artery was occluded (ie, during acute severe ischemia or during the reperfusion period)." | 1.34 | Calcium antagonist verapamil and reperfusion injury of the heart. ( Coetzee, A; Conradie, S, 2007) |
| "Verapamil does not inhibit (99m)TcN-NOET uptake in situ in normal and ischemic canine myocardium." | 1.32 | Verapamil does not inhibit 99mTcN-NOET uptake in situ in normal or ischemic canine myocardium. ( Bontron, R; Broisat, A; Fagret, D; Ghezzi, C; Mathieu, JP; Pasqualini, R; Riou, LM; Vanzetto, G, 2003) |
| "Dantrolene was protective at micromolar concentrations: tissue necrosis decreased to 21." | 1.31 | Protection of ischemic rat heart by dantrolene, an antagonist of the sarcoplasmic reticulum calcium release channel. ( Ronca, G; Ronca-Testoni, S; Yu, G; Zucchi, R, 2000) |
| "40 patients with ischemic heart disease and angina of effort (class II-III) exposed to laser therapy each 6 months for 2 years entered the study." | 1.30 | [The dynamics of blood lipid composition in patients with ischemic heart disease in the process of multiple laser therapy combined with anaprilin and verapamil administration]. ( Mironova, NA; Senatorov, IuN; Strel'tsova, NN; Vasil'ev, AP, 1997) |
| "We report on a 46-year-old male with unstable angina pectoris due to a total proximal occlusion of the left circumflex artery." | 1.30 | [Anti-ischemic effect of verapamil within the scope of interventional recanalization]. ( Baumgart, D; Caspari, G; Eggebrecht, H; Erbel, R; Haude, M; Oldenburg, O; Schaar, J, 1999) |
| " R56865 was given before ischemia and with the onset of reperfusion, applying different dosing schedules, including an initial loading dose." | 1.29 | R56865 is antifibrillatory in reperfused ischemic guinea-pig hearts, even when given only during reperfusion. ( Guttmann, I; Mozes, A; Scheufler, E; Wilffert, B, 1995) |
| " Initial dose-response studies for anipamil (0." | 1.29 | Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia. ( Guppy, LJ; Harvie, CJ; Pugsley, MK; Ries, CR; Walker, MJ, 1995) |
| "Three of 15 patients with a history of cardiac arrest or syncope had ventricular tachycardia on ambulatory ECG monitoring." | 1.29 | Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. ( Bonow, RO; Dilsizian, V; Epstein, SE; Fananapazir, L, 1993) |
| "In nexopamil-treated pigs, this was paralleled by reduced release of creatine kinase (CK) into coronary venous blood." | 1.29 | Protection of reperfused ischemic pig myocardium by nexopamil, a new combined Ca2+ and serotonin antagonist. ( Braun, M; Hohlfeld, T; Schrör, K; Strobach, H, 1994) |
| "Verapamil pretreatment resulted in values of the ATP/ADP ratio which were lower than, but not significantly different from, those observed in the control group." | 1.29 | Protective effect of verapamil on regional myocardial ischaemic injury in dog. ( Kobusiewicz, W; Ledwozyw, A; Michalak, J; Ogonowska-Kobusiewicz, M; Zywicki, W, 1995) |
| "Mibefradil is a new calcium antagonist that can inhibit cardiac calcium current without reducing myocardial force development." | 1.29 | The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation. ( Billman, GE; Hamlin, RL, 1996) |
| "Verapamil was shown to have cardioplegic and protective effects, both probably secondary to inhibition of calcium flux across the sarcolemmal membrane." | 1.26 | Effects of verapamil on myocardial tolerance to ischemic arrest: comparison to potassium arrest. ( Currie, WD; Robb-Nicholson, C; Wechsler, AS, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.87) | 18.7374 |
| 1990's | 77 (66.96) | 18.2507 |
| 2000's | 24 (20.87) | 29.6817 |
| 2010's | 12 (10.43) | 24.3611 |
| 2020's | 1 (0.87) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, P | 1 |
| Li, J | 1 |
| Liu, M | 1 |
| Zhang, M | 1 |
| Xue, Y | 1 |
| Zhang, Y | 2 |
| Han, X | 1 |
| Jing, X | 1 |
| Chu, L | 1 |
| Watanabe, I | 1 |
| Gettes, LS | 2 |
| Zhou, P | 1 |
| Zhang, SM | 1 |
| Wang, QL | 1 |
| Wu, Q | 1 |
| Chen, M | 1 |
| Pei, JM | 2 |
| Speerschneider, T | 1 |
| Thomsen, MB | 1 |
| Kawasaki, T | 1 |
| Sugihara, H | 2 |
| Seredenin, SB | 1 |
| Tsorin, IB | 1 |
| Vititnova, MB | 1 |
| Stolyaruk, VN | 1 |
| Chichkanov, GG | 1 |
| Kryzhanovskii, SA | 1 |
| Xiong, F | 1 |
| Wang, H | 1 |
| Feng, Y | 1 |
| Li, Y | 1 |
| Hua, X | 1 |
| Pang, X | 1 |
| Zhang, S | 1 |
| Song, L | 1 |
| Gu, N | 1 |
| Wilder, CD | 1 |
| Masoud, R | 1 |
| Yazar, D | 1 |
| O'Brien, BA | 1 |
| Eykyn, TR | 1 |
| Curtis, MJ | 3 |
| Smith, SM | 1 |
| Huo, T | 1 |
| Gong, Y | 1 |
| Handberg, E | 1 |
| Gulati, M | 1 |
| Merz, CN | 1 |
| Pepine, CJ | 1 |
| Cooper-DeHoff, RM | 1 |
| Gibelin, P | 1 |
| Yi, XQ | 1 |
| Li, T | 1 |
| Wang, JR | 1 |
| Wong, VK | 1 |
| Luo, P | 1 |
| Wong, IY | 1 |
| Jiang, ZH | 1 |
| Liu, L | 1 |
| Zhou, H | 1 |
| Lieu, PB | 1 |
| Fornari, M | 1 |
| Ramos, T | 1 |
| Hatcher, AS | 1 |
| Clements-Jewery, H | 1 |
| Beilei, W | 1 |
| Lin, Z | 1 |
| Qian, H | 1 |
| Qianqian, W | 1 |
| Tao, W | 1 |
| Jia, L | 1 |
| Xiaojuan, W | 1 |
| Xuting, Y | 1 |
| Liang, X | 1 |
| Liming, Z | 1 |
| Tolstikova, TG | 1 |
| Khvostov, MV | 1 |
| Bryzgalov, AO | 1 |
| Belenichev, IF | 1 |
| Pavlov, SV | 1 |
| White, WB | 2 |
| LaRocca, GM | 1 |
| Tsubokawa, A | 1 |
| Ueda, K | 1 |
| Sakamoto, H | 1 |
| Iwase, T | 1 |
| Tamaki, S | 1 |
| Gavrish, AS | 1 |
| Verbitskiĭ, VV | 1 |
| Shchul'ts, NV | 1 |
| Danilishina, MV | 1 |
| Riou, LM | 1 |
| Ghezzi, C | 1 |
| Vanzetto, G | 1 |
| Broisat, A | 1 |
| Mathieu, JP | 2 |
| Bontron, R | 1 |
| Pasqualini, R | 1 |
| Fagret, D | 1 |
| Popov, SV | 1 |
| Kandinskiĭ, ML | 1 |
| Kozlov, BN | 1 |
| Antonchenko, IV | 1 |
| Evtushenko, AV | 1 |
| Dzhavadova, GK | 1 |
| Vecherskiĭ, IuIu | 1 |
| Akhmedov, ShD | 1 |
| Afanas'ev, SA | 1 |
| Shipulin, VM | 1 |
| Churshin, AD | 1 |
| Pimenov, LT | 1 |
| Robb-Nicholson, C | 1 |
| Currie, WD | 1 |
| Wechsler, AS | 1 |
| Gatsura, SV | 1 |
| Karpov, IuA | 1 |
| Yasuda, Y | 1 |
| Maruyama, T | 1 |
| Nakamura, H | 2 |
| Arita, T | 1 |
| Ueda, N | 1 |
| Harada, M | 1 |
| Kazanskaia, GM | 1 |
| Volkov, AM | 1 |
| D'iakonitsa, TM | 1 |
| Zhdanov, GP | 1 |
| Vranic, II | 1 |
| Matic, M | 1 |
| Perunicic, J | 1 |
| Simic, T | 1 |
| Soskic, L | 1 |
| Milic, N | 1 |
| Kosicka, T | 1 |
| Kara-Perz, H | 1 |
| Głuszek, J | 1 |
| Perz, S | 1 |
| Ritchie, RH | 1 |
| Zeitz, CJ | 1 |
| Wuttke, RD | 1 |
| Hii, JT | 1 |
| Horowitz, JD | 1 |
| Abu-Fanne, R | 1 |
| Rott, D | 1 |
| Klein, M | 1 |
| Leitersdorf, E | 1 |
| Pollak, A | 1 |
| Iskendeerov, BG | 1 |
| Burmistrova, LF | 1 |
| Berenshteĭn, NV | 1 |
| Abramova, GN | 1 |
| Lokhina, TV | 1 |
| Shibaeva, TM | 1 |
| Coetzee, A | 1 |
| Conradie, S | 1 |
| Fiszer, M | 1 |
| Kołaciński, Z | 1 |
| Rechciński, T | 1 |
| Kobusiewicz, W | 2 |
| Ogonowska-Kobusiewicz, M | 2 |
| Michalak, J | 2 |
| Zywicki, W | 1 |
| Ledwozyw, A | 2 |
| Jespersen, C | 1 |
| Buffington, CW | 1 |
| Strum, DP | 1 |
| Watanabe, S | 1 |
| Hohlfeld, T | 1 |
| Braun, M | 1 |
| Strobach, H | 1 |
| Schrör, K | 1 |
| Mazur, NA | 1 |
| Pavlova, TS | 1 |
| Vasil'eva, NN | 1 |
| Kul'ginskaia, IV | 1 |
| Tabouy, L | 1 |
| Chauvet-Monges, AM | 1 |
| Salducci, MD | 1 |
| Crevat, A | 1 |
| Richard, V | 1 |
| Tron, C | 1 |
| Blanc, T | 1 |
| Thuillez, C | 1 |
| Mordovin, VF | 1 |
| Triss, SV | 1 |
| Fedorova, NA | 1 |
| Chernov, VI | 1 |
| Krylov, A | 1 |
| Pavliukova, EN | 1 |
| Karpov, RS | 1 |
| Pugsley, MK | 1 |
| Ries, CR | 1 |
| Guppy, LJ | 1 |
| Harvie, CJ | 1 |
| Walker, MJ | 1 |
| Jespersen, CM | 6 |
| Molodan, AV | 1 |
| Salgalov, AV | 1 |
| Osaulenko, VV | 1 |
| Materukhin, AN | 1 |
| Jones, DR | 1 |
| Abbott, AE | 1 |
| Hill, RC | 1 |
| Beamer, KC | 1 |
| Gustafson, RA | 1 |
| Murray, GF | 1 |
| Tan, ZT | 1 |
| Wang, XW | 2 |
| Yanagida, S | 1 |
| Ohsuzu, F | 1 |
| Sakata, N | 1 |
| Maie, S | 1 |
| Akanuma, M | 1 |
| Takayama, E | 1 |
| Hayashi, K | 1 |
| Aosaki, N | 1 |
| Fleet, WF | 1 |
| Johnson, TA | 1 |
| Cascio, WE | 1 |
| Shen, J | 1 |
| Engle, CL | 1 |
| Martin, DG | 1 |
| Vander Heide, RS | 1 |
| Schwartz, LM | 1 |
| Reimer, KA | 1 |
| Bril, A | 1 |
| Forest, MC | 1 |
| Cheval, B | 1 |
| Landais, L | 1 |
| Gout, B | 1 |
| el-Khoury, F | 1 |
| Maarek, M | 1 |
| Jean, M | 1 |
| Carrie, D | 1 |
| Foures, F | 1 |
| Elbaz, M | 1 |
| Ligou, V | 1 |
| Puel, J | 1 |
| Dilsizian, V | 1 |
| Bonow, RO | 1 |
| Epstein, SE | 1 |
| Fananapazir, L | 1 |
| Knyshov, GV | 1 |
| Vykhovaniuk, IV | 1 |
| Tkhor, NV | 1 |
| Furkalo, SN | 1 |
| Korchinskaia, OI | 1 |
| Piana, RN | 1 |
| Paik, GY | 1 |
| Moscucci, M | 1 |
| Cohen, DJ | 1 |
| Gibson, CM | 1 |
| Kugelmass, AD | 1 |
| Carrozza, JP | 1 |
| Kuntz, RE | 1 |
| Baim, DS | 1 |
| Shum-Tim, D | 1 |
| Tchervenkov, CI | 1 |
| Lough, JO | 1 |
| Chiu, RC | 1 |
| Dotzer, F | 1 |
| Gromer, H | 1 |
| Zhou, J | 1 |
| Xuan, B | 1 |
| Li, DX | 1 |
| Zhang, JL | 1 |
| Zhou, CM | 1 |
| Wang, XF | 1 |
| Pan, XQ | 1 |
| Zhang, KJ | 1 |
| Simonelli, P | 1 |
| Papa, A | 1 |
| Macciocchi, B | 1 |
| Auriemma, F | 1 |
| Vetrano, A | 1 |
| Scaletta Romeo di Santillo, M | 1 |
| Ceriello, A | 1 |
| Szilvassy, Z | 1 |
| Jakab, I | 1 |
| Ferdinandy, P | 1 |
| Koltai, M | 1 |
| Lonovics, J | 1 |
| Tarrade, T | 1 |
| Braquet, PG | 1 |
| Garlick, PB | 1 |
| Ridley, PD | 1 |
| Regen, DM | 1 |
| Howe, WC | 1 |
| Peterson, JT | 1 |
| Little, WC | 1 |
| Vaage-Nilsen, M | 2 |
| Taniguchi, Y | 1 |
| Ootsuki, K | 1 |
| Umamoto, I | 1 |
| Nakagawa, T | 1 |
| Shiga, K | 1 |
| Nakamura, T | 1 |
| Azuma, A | 1 |
| Kohno, Y | 1 |
| Nakagawa, M | 1 |
| Mattheussen, M | 1 |
| Mubagwa, K | 1 |
| Rusy, BF | 1 |
| Van Aken, H | 1 |
| Flameng, W | 1 |
| Bauza, G | 1 |
| Le Moyec, L | 1 |
| Eugène, M | 1 |
| Scheufler, E | 1 |
| Mozes, A | 1 |
| Guttmann, I | 1 |
| Wilffert, B | 1 |
| Lauerma, K | 1 |
| Saeed, M | 1 |
| Wendland, MF | 1 |
| Derugin, N | 1 |
| Yu, KK | 1 |
| Higgins, CB | 1 |
| Singh, N | 1 |
| Mironov, D | 1 |
| Goodman, S | 1 |
| Morgan, CD | 1 |
| Langer, A | 1 |
| Perchenet, L | 1 |
| Kreher, P | 1 |
| Beuckelmann, DJ | 1 |
| Billman, GE | 2 |
| Hamlin, RL | 1 |
| Yamamoto, K | 1 |
| Bando, S | 1 |
| Timour, Q | 2 |
| Freysz, M | 1 |
| Aupetit, JF | 2 |
| Loufoua, J | 2 |
| Frassati, D | 2 |
| Faucon, G | 1 |
| Nearing, BD | 1 |
| Hutter, JJ | 1 |
| Verrier, RL | 1 |
| Filep, JG | 1 |
| Skrobik, Y | 1 |
| Fournier, A | 1 |
| Földes-Filep, E | 1 |
| Conti, CR | 1 |
| Miyawaki, H | 1 |
| Zhou, X | 1 |
| Ashraf, M | 2 |
| Gonsorcík, J | 1 |
| Szakács, M | 1 |
| Palko, S | 1 |
| Mydlík, M | 1 |
| Opie, LH | 3 |
| Galenko-Iaroshevskiĭ, PA | 1 |
| Melkumova, ER | 1 |
| Bartashevich, VV | 1 |
| Uvarov, AV | 1 |
| Turovaia, AIu | 1 |
| Khankoeva, AI | 1 |
| Galygo, DS | 1 |
| Vasil'ev, AP | 1 |
| Strel'tsova, NN | 1 |
| Senatorov, IuN | 1 |
| Mironova, NA | 1 |
| De Rosa, ML | 1 |
| Giordano, A | 1 |
| Melfi, M | 1 |
| Della Guardia, D | 1 |
| Ciaburri, F | 1 |
| Rengo, F | 2 |
| Van Echteld, CJ | 1 |
| Van Emous, JG | 1 |
| Jansen, MA | 1 |
| Schreur, JH | 1 |
| Ruigrok, TJ | 1 |
| Hansen, JF | 2 |
| Pierdomenico, SD | 1 |
| Bucci, A | 1 |
| Costantini, F | 1 |
| Lapenna, D | 1 |
| Cuccurullo, F | 1 |
| Mezzetti, A | 1 |
| Muller, CA | 2 |
| McCarthy, J | 2 |
| Hofmann, D | 1 |
| Pineda, CA | 2 |
| Peisach, M | 1 |
| Headrick, JP | 1 |
| McKirdy, JC | 1 |
| Willis, RJ | 1 |
| Kraljevic, V | 1 |
| Ferrara, N | 1 |
| Longobardi, G | 1 |
| Leosco, D | 1 |
| Rosiello, R | 1 |
| Abete, P | 1 |
| Cacciatore, F | 1 |
| Guerra, N | 1 |
| Furgi, G | 1 |
| Rajaratnam, R | 1 |
| Brieger, DB | 1 |
| Hawkins, R | 1 |
| Freedman, SB | 1 |
| Sato, R | 1 |
| Yamazaki, J | 1 |
| Nagao, T | 1 |
| Wang, Y | 1 |
| Behrends, M | 1 |
| Schulz, R | 1 |
| Heusch, G | 1 |
| Di Napoli, P | 2 |
| Ranalli, G | 1 |
| Di Crecchio, A | 2 |
| Taccardi, AA | 2 |
| Ausiello, A | 1 |
| Di Muzio, M | 2 |
| Barsotti, A | 2 |
| Farkas, A | 1 |
| Qureshi, A | 1 |
| Furuya, M | 1 |
| Yoshida, K | 1 |
| Forslund, L | 1 |
| Hjemdahl, P | 1 |
| Held, C | 1 |
| Eriksson, SV | 1 |
| Björkander, I | 1 |
| Rehnqvist, N | 1 |
| Contegiacomo, G | 1 |
| Tiloca, P | 1 |
| Maggi, A | 1 |
| Oldenburg, O | 1 |
| Baumgart, D | 1 |
| Schaar, J | 1 |
| Eggebrecht, H | 1 |
| Caspari, G | 1 |
| Haude, M | 1 |
| Erbel, R | 1 |
| Bui-Xuan, B | 1 |
| Kioueh, I | 1 |
| Yu, G | 1 |
| Zucchi, R | 1 |
| Ronca-Testoni, S | 1 |
| Ronca, G | 1 |
| Glasser, SP | 1 |
| Frishman, W | 1 |
| Stone, P | 1 |
| Johnson, MF | 1 |
| Grasic Kuhar, C | 1 |
| Budihna, MV | 1 |
| Blidaru, M | 1 |
| Cuparencu, B | 1 |
| Pleşca-Manea, L | 1 |
| Novo, S | 1 |
| Abrignani, MG | 1 |
| Novo, G | 1 |
| Nardi, E | 1 |
| Dominguez, LJ | 1 |
| Strano, A | 1 |
| Barbagallo, M | 1 |
| Zhou, SS | 1 |
| Niu, GB | 1 |
| Zhu, MZ | 1 |
| Zang, YM | 1 |
| Voronkov, LG | 1 |
| Lysenko, AF | 1 |
| Arvieux, CC | 1 |
| Pernin, C | 1 |
| Drouet, N | 1 |
| Hamant, S | 1 |
| Dubois, F | 1 |
| Cuchet, P | 1 |
| Stieglitz, P | 1 |
| Comet, M | 1 |
| Moiseev, VS | 1 |
| Moiseev, SV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction[NCT02435797] | Phase 4 | 100 participants (Anticipated) | Interventional | 2015-04-30 | Recruiting | ||
| A Randomized, Open Label, Parallel-group Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Di[NCT05427786] | Phase 4 | 460 participants (Anticipated) | Interventional | 2022-12-14 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for verapamil and Myocardial Ischemia
| Article | Year |
|---|---|
Subendocardial ischemia in hypertrophic cardiomyopathy.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cardiomyopathy, Hypertrophic; Diagnostic Imaging; Diltiazem | 2014 |
Chronopharmacology of cardiovascular therapy.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Blood Pressu | 2002 |
[Ischemic heart disease combined with hypertension: peculiarities of course and selection of therapy].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
[Indications for calcium channel antagonist therapy according to the latest large clinical trials].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Antihypertensive Agents; Calcium Channel Blockers; Cli | 2005 |
[Post-infarction, myocardial ischemia: clinical importance and risk factor].
Topics: Arrhythmias, Cardiac; Humans; Myocardial Infarction; Myocardial Ischemia; Risk Factors; Verapamil | 1995 |
[Anti-ischemic therapy with verapamil. Improving prognosis by secondary prevention after acute myocardial infarct].
Topics: Coronary Circulation; Drug Therapy, Combination; Humans; Myocardial Infarction; Myocardial Ischemia; | 1993 |
Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil.
Topics: Arrhythmias, Cardiac; Calcium Channel Blockers; Coronary Disease; Heart Failure; Humans; Myocardial | 1996 |
Anti-ischaemic intervention with verapamil in patients recovering from acute myocardial infarction.
Topics: Angina Pectoris; Calcium Channel Blockers; Humans; Myocardial Infarction; Myocardial Ischemia; Preva | 1995 |
Re-examining the clinical safety and roles of calcium antagonists in cardiovascular medicine.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiovascular Diseases; Cor | 1996 |
Calcium channel blockers for hypertension: dissecting the evidence for adverse effects.
Topics: Calcium Channel Blockers; Catecholamines; Cerebrovascular Disorders; Drug Evaluation; Gastrointestin | 1997 |
Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Clinica | 1998 |
Circadian heart rate response to chronotherapy versus conventional therapy in patients with hypertension and myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amlodipine; Atenolol; Blood Pressure; C | 2000 |
[Verapamil--on the 30th anniversary of its clinical use].
Topics: Arrhythmias, Cardiac; Arteriosclerosis; History, 20th Century; Humans; Hypertension; Myocardial Isch | 1992 |
18 trials available for verapamil and Myocardial Ischemia
| Article | Year |
|---|---|
Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy.
Topics: Aged; Angina Pectoris; Atherectomy, Coronary; Coronary Angiography; Coronary Circulation; Coronary S | 2002 |
[Clinical efficacy of myocardial cytoprotector trimetazidine in peri- and postmenopausal women with ischemic heart disease].
Topics: Aged; Drug Therapy, Combination; Female; Humans; Middle Aged; Myocardial Ischemia; Postmenopause; Pr | 2003 |
Adenosine cardioprotection study in clinical setting of paroxysmal supraventricular tachycardia.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adult; Cardiotonic Agents; Female; Humans; Male; Middle Age | 2006 |
[Evaluation of hypotensive and antiischemic effects of a combination of dihydropyridine and non-dihydropyridine calcium antagonists in patients suffering from coronary artery disease with arterial hypertension].
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Coronary Circulation; Drug Therap | 2006 |
[The comparative efficacy of verapamil, nifedipine and propranolol in patients with IHD and an enhanced risk of a fatal outcome].
Topics: Adult; Cardiac Complexes, Premature; Electrocardiography, Ambulatory; Exercise Tolerance; Humans; Ma | 1994 |
Role of ischemia in postinfarction heart failure: hypothetical considerations based on use of verapamil in the DAVIT II Study. Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Angina Pectoris; Computer Communication Networks; Double-Blind Method; Heart Failure; Humans; Myocar | 1994 |
[Treatment of ischemic heart disease in the elderly. Comparison of diltiazem, verapamil and gallopamil].
Topics: Age Factors; Aged; Angina Pectoris; Coronary Angiography; Coronary Disease; Diltiazem; Drug Evaluati | 1993 |
Ventricular arrhythmias in patients recovering from myocardial infarction: do residual myocardial ischemia and anti-ischemic medical intervention influence the one-month prevalence? The Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Aged; Arrhythmias, Cardiac; Double-Blind Method; Electrocardiography, Ambulatory; Exercise Test; Fem | 1993 |
Treatment of silent ischemia in unstable angina: a randomized comparison of sustained-release verapamil versus metoprolol.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Calcium Channel Blockers; Delayed-Action Prepar | 1995 |
Antianginal efficacy over 24 hours and exercise hemodynamic effects of once daily sustained-release 300 mg diltiazem and 240 mg verapamil in stable angina pectoris.
Topics: Aged; Angina Pectoris; Calcium Channel Blockers; Cross-Over Studies; Delayed-Action Preparations; Di | 1998 |
Congestive heart failure and ischaemic heart disease treated with trandolapril and verapamil. DAVIT Study Group. Danish Verapamil Infarction Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Clinica | 1998 |
Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease.
Topics: Antihypertensive Agents; Atenolol; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian | 1998 |
Verapamil reduces dipyridamole-induced myocardial ischemia in patients with coronary artery disease.
Topics: Aged; Calcium Channel Blockers; Coronary Angiography; Coronary Disease; Dipyridamole; Echocardiograp | 1999 |
Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; | 1999 |
Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]).
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Elect | 1999 |
Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Blood | 2001 |
[Effect of various antianginal agents on the frequency and duration of myocardial ischemic episodes in patients with stable angina pectoris].
Topics: Angina Pectoris; Drug Therapy, Combination; Humans; Myocardial Ischemia; Nifedipine; Periodicity; Pr | 1992 |
The significance of myocardial ischaemia and verapamil treatment on the prevalence of supraventricular tachyarrhythmias in patients recovering from acute myocardial infarction. Danish Study Group on Verapamil in Myocardial Infarction.
Topics: Double-Blind Method; Electrocardiography, Ambulatory; Exercise Test; Female; Humans; Male; Middle Ag | 1992 |
85 other studies available for verapamil and Myocardial Ischemia
| Article | Year |
|---|---|
Hesperetin modulates the Sirt1/Nrf2 signaling pathway in counteracting myocardial ischemia through suppression of oxidative stress, inflammation, and apoptosis.
Topics: Animals; Antioxidants; Apoptosis; Dose-Response Relationship, Drug; Electrocardiography; Heart Funct | 2021 |
Effects of Propranolol and Verapamil on Changes in TQ and ST Segment Potentials During Graded Coronary Flow Reduction in a Porcine Myocardial Ischemia Model.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Channel Blockers; Disease Models, Animal; Electrocardi | 2017 |
Anti-arrhythmic effect of verapamil is accompanied by preservation of cx43 protein in rat heart.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2013 |
Physiology and analysis of the electrocardiographic T wave in mice.
Topics: Adrenergic beta-Agonists; Animals; Calcium Channel Blockers; Chronic Disease; Disease Models, Animal | 2013 |
On the mechanism of anti-ischemic effects of afobazole.
Topics: Administration, Intravenous; Animals; Animals, Outbred Strains; Anti-Arrhythmia Agents; Benzimidazol | 2013 |
Cardioprotective activity of iron oxide nanoparticles.
Topics: Animals; Cardiotonic Agents; Cells, Cultured; Drug Evaluation, Preclinical; Female; Ferric Compounds | 2015 |
Contractile function assessment by intraventricular balloon alters the ability of regional ischaemia to evoke ventricular fibrillation.
Topics: Animals; Cardiac Catheters; Electrocardiography; Lactic Acid; Magnetic Resonance Spectroscopy; Male; | 2016 |
Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Coronary Artery Disease; Drug Resistance; Fema | 2016 |
[Drug treatment for hypertrophic cardiomyopathy].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiomyop | 2009 |
Total ginsenosides increase coronary perfusion flow in isolated rat hearts through activation of PI3K/Akt-eNOS signaling.
Topics: Animals; Coronary Circulation; Coronary Vessels; Dose-Response Relationship, Drug; Endothelial Cells | 2010 |
Reduced antiarrhythmic efficacy of verapamil in isolated rat hearts in the presence of elevated extracellular calcium.
Topics: Animals; Anti-Arrhythmia Agents; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Male; | 2011 |
Direct cardiac toxicity of the tentacle-only extract from the jellyfish Cyanea capillata demonstrated in isolated rat heart.
Topics: Animals; Calcium Channels, L-Type; Cnidarian Venoms; Coronary Vasospasm; Dose-Response Relationship, | 2012 |
Glycidipine, a promising hypotensive and cardioprotective agent.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Cardiotonic Agents; Drug Combinations; Dru | 2011 |
[Effect of long term administration of finoptin on the morphofunctional state of working cells of the intact myocardium in modeling of chronic coronary insufficiency].
Topics: Animals; Calcium; Calcium Channel Blockers; Chronic Disease; Disease Models, Animal; Drug Evaluation | 2002 |
Verapamil does not inhibit 99mTcN-NOET uptake in situ in normal or ischemic canine myocardium.
Topics: Adenosine; Animals; Blood Flow Velocity; Coronary Circulation; Dogs; Heart; Myocardial Ischemia; Myo | 2003 |
[Effect of calcium antagonists verapamil and amlodipine on the risk of development of atrial fibrillation after coronary artery bypass grafting].
Topics: Adult; Aged; Amlodipine; Atrial Fibrillation; Calcium Channel Blockers; Coronary Artery Bypass; Huma | 2003 |
Effects of verapamil on myocardial tolerance to ischemic arrest: comparison to potassium arrest.
Topics: Animals; Calcium Channel Blockers; Cardioplegic Solutions; Heart; Heart Arrest, Induced; Models, Ani | 1978 |
Oxygen-dependent mechanisms underlying the antiischemic effect of verapamil and amlodipine.
Topics: Amlodipine; Animals; Hemoglobins; Lipid Peroxidation; Malondialdehyde; Myocardial Infarction; Myocar | 2004 |
Pathophysiological basis for monitoring of whole heart conductance by 2-lead system.
Topics: Animals; Calcium; Electric Countershock; Electrodes; Heart Atria; Heart Conduction System; Heptanol; | 2006 |
[Endothelium of myocardium microvessel under conditions of hypothermia, ischemia, reperfusion and pharmaco-cold cardioplegia with calcium antagonist].
Topics: Calcium Channel Blockers; Cardioplegic Solutions; Coronary Vessels; Endothelium, Vascular; Heart Atr | 2005 |
Attenuation of the negative inotropic effects of metoprolol at short cycle lengths in humans: comparison with sotalol and verapamil.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Catheterization; Cardiac Pacing, Artificial; Female; Hemodynam | 2006 |
Recurrent apical ballooning despite treatment with verapamil.
Topics: Aged; Calcium Channel Blockers; Cardiomyopathies; Coronary Angiography; Diagnosis, Differential; Ele | 2007 |
Calcium antagonist verapamil and reperfusion injury of the heart.
Topics: Adenosine Triphosphate; Animals; Calcium Channel Blockers; Coronary Circulation; Myocardial Ischemia | 2007 |
[The application of 4-aminopyridine in calcium channel inhibitors acute poisoning].
Topics: 4-Aminopyridine; Acute Disease; Adrenergic beta-Antagonists; Adult; Antidotes; Antihypertensive Agen | 2007 |
Protective effect of verapamil on regional myocardial ischaemic injury in dog.
Topics: Animals; Calcium Channel Blockers; Cell Membrane; Dog Diseases; Dogs; Fatty Acids, Nonesterified; He | 1995 |
Regional oxygen consumption persists in dyskinetic canine myocardium.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Citrates; Coronary Circulation; Diacetyl; Dogs; H | 1994 |
Protection of reperfused ischemic pig myocardium by nexopamil, a new combined Ca2+ and serotonin antagonist.
Topics: Animals; Blood Platelets; Calcium Channel Blockers; Creatine Kinase; Diastole; Epoprostenol; Female; | 1994 |
Protective effect of some calcium antagonists against mitochondrial calcium injury.
Topics: Adenosine Triphosphate; Amlodipine; Animals; Antihypertensive Agents; Bepridil; Calcium Channel Bloc | 1994 |
Infarct size-limiting properties of Ro 40-5967, a novel nondihydropyridine calcium channel, in anesthetized rats: comparison with verapamil.
Topics: Anesthesia; Animals; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Heart Rate; Hemodynam | 1995 |
[An evaluation of the efficacy of treating IHD patients with calcium antagonists].
Topics: Adult; Calcium Channel Blockers; Delayed-Action Preparations; Drug Evaluation; Echocardiography; Ele | 1995 |
Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blocker | 1995 |
[The preoperative drug correction of disorders in myocardial functional reserve in patients with ischemic heart disease].
Topics: Adult; Amiodarone; Combined Modality Therapy; Coronary Artery Bypass; Drug Therapy, Combination; Hea | 1994 |
Preservation of adenosine 5'-triphosphate and mitochondrial function during hypercalcemic reperfusion using verapamil cardioplegia.
Topics: Adenosine Triphosphate; Animals; Aorta; Blood Flow Velocity; Blood Pressure; Calcium; Heart Arrest, | 1995 |
Verapamil, ribose and adenine enhance resynthesis of postischemic myocardial ATP.
Topics: Adenine; Adenine Nucleotides; Adenosine Triphosphate; Animals; Calcium; Heart; Male; Myocardial Isch | 1994 |
Protective effects of verapamil and adenosine treatment on high energy phosphate metabolism in ischemic and reperfused myocardium.
Topics: Adenosine; Animals; Energy Metabolism; In Vitro Techniques; Magnetic Resonance Spectroscopy; Male; M | 1994 |
Marked activation delay caused by ischemia initiated after regional K+ elevation in in situ pig hearts.
Topics: Animals; Epinephrine; Female; Glyburide; Heart; Heart Conduction System; Male; Myocardial Ischemia; | 1994 |
The novel calcium antagonist Ro 40-5967 limits myocardial infarct size in the dog.
Topics: Animals; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Dogs; Female; Heart; Heart Rate; | 1994 |
Effect of zatebradine, a specific bradycardic agent, on ischemia-induced arrhythmias in anesthetized rabbits.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Benzazepines; Cardiovascular Agents; Dogs; Dose-Re | 1994 |
[Electrocardiographic evaluation of anti-ischemic effect of verapamil during angioplasty].
Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Electrocardiography; Female; Humans; I | 1994 |
Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Cardiac Pacing, Artificial; Cardiomyopathy, Hypertro | 1993 |
[Hemodynamic basis of antianginal effect of calcium antagonists in patients with ischemic heart disease after aortocoronary shunting: myocardial reserve potentials and their mechanisms].
Topics: Adult; Angina Pectoris; Coronary Artery Bypass; Dose-Response Relationship, Drug; Exercise Test; Hem | 1993 |
Incidence and treatment of 'no-reflow' after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Coronary Vessels; Humans; Incidence; Myocardial Ischemia; Retrospect | 1994 |
Newborn myocardial protection after prolonged prearrest cooling: a calcium overload phenomenon?
Topics: Animals; Animals, Newborn; Calcium; Cold Temperature; Heart; Heart Rate; Myocardial Ischemia; Myocar | 1994 |
Effects of tetrahydroberberine on ischemic and reperfused myocardium in rats.
Topics: Animals; Anti-Arrhythmia Agents; Berberine; Berberine Alkaloids; In Vitro Techniques; Male; Malondia | 1993 |
[Cardioprotection of 2-[p-(dimethylamino)styryl]pyridine methiodide against ischemic damage and myocardial lipid peroxidation].
Topics: Animals; Calcium Channel Blockers; Female; Isoproterenol; Lipid Peroxidation; Male; Mice; Mice, Inbr | 1993 |
Zaprinast, cicletanine, and verapamil attenuate overdrive pacing-induced myocardial ischemia in conscious rabbits.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Cardiac Pacing, A | 1993 |
Anion manipulation, a novel antiarrhythmic approach: mechanism of action.
Topics: Animals; Anions; Blood Pressure; Bromides; Chlorides; Coronary Circulation; Cyclic AMP; Cyclic GMP; | 1993 |
Characteristics of single isovolumic left-ventricular pressure waves of dog hearts in situ.
Topics: Animals; Blood Pressure; Cardiac Output; Cardiac Pacing, Artificial; Computer Simulation; Dobutamine | 1993 |
[Effect of verapamil on myocardial ischemia in patients with hypertrophic cardiomyopathy: evaluation by exercise 201Tl SPECT].
Topics: Adult; Blood Pressure; Cardiomyopathy, Hypertrophic; Exercise Test; Female; Heart; Heart Rate; Human | 1993 |
Potentiated state contractions in isolated hearts: effects of ischemia and reperfusion.
Topics: Animals; Calcium; Cardiac Pacing, Artificial; Heart; In Vitro Techniques; Myocardial Contraction; My | 1993 |
pH regulation during ischaemia-reperfusion of isolated rat hearts, and metabolic effects of 2,3-butanedione monoxime.
Topics: Adenosine Triphosphate; Animals; Bicarbonates; Carrier Proteins; Diacetyl; Heart; Hydrogen-Ion Conce | 1995 |
R56865 is antifibrillatory in reperfused ischemic guinea-pig hearts, even when given only during reperfusion.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzothiazoles; Calcium; Calcium Channel Block | 1995 |
Verapamil reduces the size of reperfused ischemically injured myocardium in hypertrophied rat hearts as assessed by magnetic resonance imaging.
Topics: Animals; Aorta, Abdominal; Calcium Channel Blockers; Coloring Agents; Contrast Media; Disease Models | 1996 |
Mechanical and electrophysiological effects of preconditioning in isolated ischemic/reperfused rat hearts.
Topics: 4-Aminopyridine; Action Potentials; Animals; Female; Heart; Myocardial Contraction; Myocardial Ische | 1995 |
[Calcium antagonist protects the heart from ischemia and thrombosis].
Topics: Angina Pectoris; Calcium Channel Blockers; Coronary Thrombosis; Dose-Response Relationship, Drug; Hu | 1996 |
The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation.
Topics: Animals; Arrhythmias, Cardiac; Benzimidazoles; Calcium Channel Blockers; Diltiazem; Dogs; Dose-Respo | 1996 |
Effects of verapamil and magnesium sulfate on electrophysiologic changes during acute myocardial ischemia and following reperfusion in dogs: comparative effects of administration by intravenous and coronary sinus retroperfusion routes.
Topics: Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Coronary Vessels; Dogs; Electrophysiology | 1996 |
[Value of calcium channel blockers in the prevention of ventricular fibrillation of ischemic etiology: experimental arguments].
Topics: Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Death, Sudden, Cardiac; Hemodynamics; Hum | 1996 |
Potent antifibrillatory effect of combined blockade of calcium channels and 5-HT2 receptors with nexopamil during myocardial ischemia and reperfusion in dogs: comparison to diltiazem.
Topics: Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Coronary Circulation; Diltiazem; Dogs; El | 1996 |
Effects of calcium antagonists on endothelin-1-induced myocardial ischaemia and oedema in the rat.
Topics: Albumins; Animals; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Edema | 1996 |
Is a combination of verapamil and an ACE-inhibitor the optimal solution in ischaemic heart failure?
Topics: Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Calcium Channel Blockers; Clinical T | 1995 |
Calcium preconditioning elicits strong protection against ischemic injury via protein kinase C signaling pathway.
Topics: Animals; Calcium; Calcium Channel Blockers; Fluorescent Antibody Technique; In Vitro Techniques; Mal | 1996 |
The influence of nifedipine and verapamil on the ischaemia-induced changes in canine sarcolemmal membranes.
Topics: Animals; Calcium Channel Blockers; Calcium-Transporting ATPases; Cell Membrane; Dog Diseases; Dogs; | 1995 |
[Pharmacotherapy of silent myocardial ischemia in patients on hemodialysis].
Topics: Adrenergic beta-Agonists; Adult; Aged; Calcium Channel Blockers; Female; Humans; Kidney Failure, Chr | 1996 |
[Comparative evaluation of the effect of dimebon, obzidan, finoptin, and cordarone on the functional state of the ischemic focus and the size of necrosis zone during experimental myocardial infarction].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cats; Histamine H1 Antagonists; Indoles; Myocardial Inf | 1996 |
[The dynamics of blood lipid composition in patients with ischemic heart disease in the process of multiple laser therapy combined with anaprilin and verapamil administration].
Topics: Cholesterol; Combined Modality Therapy; Humans; Infrared Rays; Laser Therapy; Male; Middle Aged; Myo | 1997 |
Manipulation of intracellular sodium by extracellular divalent cations: a 23Na and 31P NMR study on intact rat hearts.
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Channel Blockers; Calcium Chloride; Cations, Dival | 1998 |
Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise.
Topics: Animals; Benzimidazoles; Calcium Channel Blockers; Dose-Response Relationship, Drug; Electrocardiogr | 1998 |
Functional and metabolic effects of extracellular magnesium in normoxic and ischemic myocardium.
Topics: Adenosine Triphosphate; Animals; Calcium; Cytosol; Depression, Chemical; Extracellular Space; Magnes | 1998 |
Combination of a calcium antagonist, verapamil, with an angiotensin converting enzyme inhibitor, trandolapril, in experimental myocardial ischemia and reperfusion: antiarrhythmic and hemodynamic effects of chronic oral pretreatment.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Cal | 1998 |
Temporal differences in actions of calcium channel blockers on K+ accumulation, cardiac function, and high-energy phosphate levels in ischemic guinea pig hearts.
Topics: Acidosis; Adenosine Triphosphate; Animals; Calcium Channel Blockers; Depression, Chemical; Diltiazem | 1999 |
Role of protein kinase C in mitochondrial KATP channel-mediated protection against Ca2+ overload injury in rat myocardium.
Topics: Adenosine Triphosphate; Alkaloids; Animals; Benzophenanthridines; Calcium; Calcium Channel Blockers; | 1999 |
Effects of verapamil and mibefradil on regional blood flow and function in normal and ischemic myocardium.
Topics: Benzimidazoles; Calcium Channel Blockers; Coronary Circulation; Heart Function Tests; Humans; Mibefr | 1999 |
[The effects of verapamil on the postischemic changes in the coronary microcirculation: the role of nitric oxide].
Topics: Animals; Calcium Channel Blockers; Coronary Circulation; In Vitro Techniques; Male; Microcirculation | 1999 |
Inadequate ischaemia-selectivity limits the antiarrhythmic efficacy of mibefradil during regional ischaemia and reperfusion in the rat isolated perfused heart.
Topics: Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channel | 1999 |
[Comparison of effects of verapamil and those of nicardipine on myocardial ischemia and reperfusion injury: a study in an in situ rabbit model].
Topics: Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Disease Models, Animal; Myocardial Ischem | 1999 |
Endothelial protective effect of verapamil against acute myocardial contractile dysfunction in isolated working rat hearts subjected to global ischemia.
Topics: Animals; Blood Pressure; Coronary Circulation; Endothelium, Vascular; Heart; Heart Rate; Hemodynamic | 1998 |
[Anti-ischemic effect of verapamil within the scope of interventional recanalization].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Blood Flow Velocity; Calcium Channel Blockers; Cor | 1999 |
Opposite change with ischaemia in the antifibrillatory effects of class I and class IV antiarrhythmic drugs resulting from the alteration in ion transmembrane exchanges related to depolarization.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Flecainide; Myocardial | 2000 |
Protection of ischemic rat heart by dantrolene, an antagonist of the sarcoplasmic reticulum calcium release channel.
Topics: Animals; Calcium; Dantrolene; Heart; Hemodynamics; Male; Myocardial Ischemia; Rats; Rats, Wistar; Ry | 2000 |
Effects of mibefradil and verapamil on ischemic-reperfusion in the hearts of guinea pigs with acute renal failure.
Topics: Acute Kidney Injury; Animals; Calcium Channel Blockers; Coronary Circulation; Female; Guinea Pigs; L | 2000 |
The influence of intracerebroventricular administration of (+/-) propranolol and (+/-) verapamil on experimental myocardial ischemia and necrosis in rats.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Female; Injections, Intr | 2000 |
[Effects of tetraethylammonium chloride and verapamil on the effective refractory period of ischemic myocardium in rabbits].
Topics: Animals; Female; Male; Myocardial Ischemia; Rabbits; Refractory Period, Electrophysiological; Tetrae | 1992 |
Comparative effects of halothane associated with verapamil and ischaemia on myocardial metabolism in isolated perfused rat hearts.
Topics: Animals; Blood Pressure; Drug Combinations; Halothane; Heart Rate; Iodine Radioisotopes; Lipids; Mal | 1992 |
Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation.
Topics: Animals; Benzimidazoles; Binding Sites; Calcium Channel Blockers; Coronary Circulation; Diltiazem; D | 1992 |